The benefits of breast milk are well known, but why breastfeeding protects against various forms of cancer remains a mystery.
A new study in the Journal of Human Lactation found high levels of cancer-fighting TNF-related apoptosis inducing ligand (TRAIL) in human milk, which might be one source of breast milk's anticancer activity.
Researchers took samples of colostrum, the first milk available to newborns, and of mature breast milk from new mothers.
Researchers then obtained samples of blood from healthy women, and various ready-to-feed infant formulas.
The colostrum, mature breast milk, blood and formula were then all tested to measure their level of TRAIL.
The researchers found that colostrum and breast milk contained 400- and 100-fold, respectively, higher levels of TRAIL than blood. No TRAIL was detected in the formula.
"The important role of breastfeeding in the prevention of certain childhood cancers, such as lymphoblastic leukaemia, Hodgkin's disease, and neuroblastoma, has been previously demonstrated," wrote the authors. "However, endogenous soluble TRAIL represents a strong candidate to explain the overall biological effect of breastfeeding against cancer."
Mothers chosen to participate in the study were eligible because they exhibited no signs of eclampsia, infection, or fever, and delivered healthy newborns at term.
The authors wrote, "To our knowledge, this is the first time that TRAIL has been measured in colostrum and human breast milk. This study has revealed much higher TRAIL concentrations in colostrum and breast milk compared to the levels of circulating serum TRAIL."
Source: SAGE Publications
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.